For example, the SMO inhibitor vismodegib, one of few targeted drugs approved for SHH medulloblastoma, is ineffective against TP53-mutant, MYCN-amplified or GLI2-amplified tumors54, each of which were recurrent features of ecDNA+ medulloblastoma in our patient cohort. The gene discussed is MYCN; the disease is medulloblastoma.